No results for ‘’
Aurobindo Pharma Ltd
₹1497.80
(3.75%)
Sun, 21 Jun 2026, 07:41 am
Health Technology
Pharmaceuticals: Other
24.5KAurobindo Pharma PE Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 54.53 | 22.44 | 8.25 | 23.95 | 10.80 | 10.93 | 0 | 14.46 | 12.70 | 22.60 | 21.49 | 17.17 | 13.47 | 19.48 | 8.51 | 9.68 | 14.80 | 15.75 | 20.12 | 19.39 |
| Price to book ratio | 4.46 | 4.09 | 1.39 | 0.82 | 2.92 | 2.33 | 1.48 | 1.63 | 3.97 | 6.91 | 5.98 | 4.22 | 2.80 | 3.32 | 1.44 | 2.36 | 1.59 | 1.13 | 2.14 | 2.06 |
| Price to sales ratio | 2.42 | 2.13 | 0.81 | 0.40 | 1.72 | 1.45 | 0.76 | 0.74 | 1.86 | 2.96 | 3.22 | 2.69 | 2.01 | 2.39 | 1.06 | 2.10 | 1.67 | 1.23 | 2.22 | 2.15 |
| Price to cash flow ratio | 0 | 0 | 13.90 | 16.15 | 16.15 | 20.81 | 13.51 | 25.82 | 26.78 | 30.21 | 32.33 | 12.21 | 17.11 | 30.77 | 5.66 | 15.65 | 7.80 | 12.53 | 25.90 | 17.55 |
| Enterprise value | 4979Cr | 6012Cr | 3542Cr | 3445Cr | 8156Cr | 7906Cr | 6407Cr | 7425Cr | 18512Cr | 39592Cr | 47773Cr | 42355Cr | 36161Cr | 51066Cr | 27298Cr | 51356Cr | 37905Cr | 29415Cr | 64162Cr | 67616Cr |
| Enterprise value to EBITDA ratio | 31.86 | 21.18 | 11.15 | 6.34 | 10.59 | 8.54 | 11.92 | 8.89 | 8.92 | 15.77 | 16.06 | 13.11 | 10.10 | 13.82 | 5.61 | 9.47 | 8.51 | 7.70 | 11.23 | 10.49 |
| Debt to equity ratio | 1.69 | 2.35 | 1.65 | 1.89 | 1.18 | 0.74 | 1.29 | 1.29 | 1.01 | 0.86 | 0.69 | 0.36 | 0.41 | 0.50 | 0.35 | 0.24 | 0.13 | 0.20 | 0.22 | 0.25 |
| Return on equity % | 9.34 | 23.63 | 23.73 | 4.34 | 36.56 | 26.85 | -5.16 | 11.88 | 36.91 | 35.39 | 32.55 | 27.63 | 23.02 | 18.50 | 18.53 | 27.54 | 11.39 | 7.50 | 11.20 | 11.16 |
Aurobindo Pharma Ltd Price to Earnings Ratio
The Aurobindo Pharma Ltd Price to Earnings Ratio is a key financial metric used by investors to evaluate Aurobindo Pharma Ltd's valuation, profitability, and overall financial performance. Tracking the Aurobindo Pharma Ltd Price to Earnings Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Aurobindo Pharma Ltd (NSE: AUROPHARMA, BSE: 524804) is currently trading at ₹1497.80, with a market capitalization of ₹83812.58Cr. As a leading company in the Health technology sector and Pharmaceuticals: other industry, monitoring the Aurobindo Pharma Ltd Price to Earnings Ratio is essential for fundamental analysis.
Aurobindo Pharma Ltd Price to Earnings Ratio Current Value
The current Aurobindo Pharma Ltd Price to Earnings Ratio stands at 19.39.
The Aurobindo Pharma Ltd Price to Earnings Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Aurobindo Pharma Ltd Price to Earnings Ratio Historical Trend
The Aurobindo Pharma Ltd Price to Earnings Ratio has shown the following historical trend:
- 2024: 19.39
- 2023: 20.12
- 2022: 15.75
- 2021: 14.80
- 2020: 9.68
The decline in Aurobindo Pharma Ltd Price to Earnings Ratio indicates improving financial efficiency or better earnings growth.
What Aurobindo Pharma Ltd Price to Earnings Ratio Indicates for Investors
The Aurobindo Pharma Ltd Price to Earnings Ratio plays a crucial role in understanding the company's financial health and valuation.
A higher P/E ratio indicates investors expect strong future earnings growth, while a lower ratio may signal undervaluation.
Aurobindo Pharma Ltd Price to Earnings Ratio Analysis Summary
The Aurobindo Pharma Ltd Price to Earnings Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Aurobindo Pharma Ltd Price to Earnings Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Aurobindo Pharma Ltd Price to Earnings Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.